Publishing research using ab2356? Please let us know so that we can cite the reference in this datasheet.

ab2356 has been referenced in 20 publications.

  • Popp I  et al. Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF. BMC Med Genet 19:7 (2018). PubMed: 29325523
  • Zhu B  et al. The protective role of DOT1L in UV-induced melanomagenesis. Nat Commun 9:259 (2018). PubMed: 29343685
  • He L  et al. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells. Int J Biochem Cell Biol 100:54-60 (2018). WB . PubMed: 29768183
  • Ramanathan RK  et al. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 8:925-935 (2017). IHC ; Human . PubMed: 29299351
  • Okuda K  et al. Expression of excision repair cross-complementation group 1 and class III ß-tubulin in thymic carcinoma. Oncol Lett 13:3144-3150 (2017). IHC ; Human . PubMed: 28521419
  • He D  et al. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer. Oncol Lett 14:3463-3472 (2017). PubMed: 28927101
  • Kim DH  et al. High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer. Oncol Lett 14:4995-5003 (2017). PubMed: 28943968
  • Millis SZ  et al. Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. Biomark Cancer 7:69-76 (2015). ICC/IF ; Human . PubMed: 26715866
  • Li C  et al. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer. Tumour Biol N/A:N/A (2014). IHC-P ; Human . PubMed: 25217323
  • Muallem MZ  et al. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Anticancer Res 34:401-6 (2014). Human . PubMed: 24403494
  • Li P  et al. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer 108:1238-44 (2013). IHC-P ; Human . PubMed: 23481186
  • Patel MR  et al. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 149:587-95 (2013). IHC ; Human . PubMed: 23846458
  • Kaira K  et al. The role of ßIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 18:371-9 (2013). PubMed: 22358390
  • Zajchowski DA  et al. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11:492-502 (2012). IHC-P ; Human . PubMed: 22203729
  • Kaira K  et al. Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Res 31:2763-71 (2011). IHC ; Human . PubMed: 21868518
  • Mohni KN  et al. DNA mismatch repair proteins are required for efficient herpes simplex virus 1 replication. J Virol 85:12241-53 (2011). WB ; Rat . PubMed: 21957315
  • Koo JS & Kim H Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary. Tumour Biol 32:893-904 (2011). IHC-P ; Human . PubMed: 21598042
  • Paul C  et al. Aging results in differential regulation of DNA repair pathways in pachytene spermatocytes in the Brown Norway rat. Biol Reprod 85:1269-78 (2011). WB ; Rat . PubMed: 21865553
  • Hayes M  et al. ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation. Anticancer Res 31:4135-9 (2011). IHC . PubMed: 22199271
  • McGurk CJ  et al. Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97:1121-36 (2006). PubMed: 16315315


Sign up